208
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

      , , , , , ,
      Schizophrenia Research
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We used L-(quinoxalin-6-ylcarbonyl)piperidine (CX516) (a modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptor) as a sole agent in a double blind placebo-controlled design in a small series of patients with schizophrenia who were partially refractory to treatment with traditional neuroleptics. The study entailed weekly increments in doses of CX516, from 300 mg tid for week 1 up to 900 mg tid on week 4. Patients were followed with clinical ratings, neuropsychological testing, and were monitored for adverse events. Four patients received 2 to 4 weeks of CX516, two received placebo and two withdrew during the placebo phase. Adverse events associated with drug administration were transient and included leukopenia in one patient and elevation in liver enzymes in another. No clear improvement in psychosis or in cognition was observed over the course of the study. CX516 at the doses tested did not appear to yield dramatic effects as a sole agent, but inference from this study is limited.

          Related collections

          Author and article information

          Journal
          Schizophrenia Research
          Schizophrenia Research
          Elsevier BV
          09209964
          October 2002
          October 2002
          : 57
          : 2-3
          : 221-226
          Article
          10.1016/S0920-9964(01)00311-5
          12223253
          7ac0e714-2433-43d4-a1e9-86ae60beaec0
          © 2002

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article